- |||||||||| ivermectin oral / Generic mfg.
Review, Journal: Antiviral therapy for COVID-19 virus: A narrative review and bibliometric analysis. (Pubmed Central) - Oct 30, 2024
Furthermore, this study examines the published literature about the pharmacological interventions for the novel coronavirus disease 2019 (COVID-19), explicitly focusing on the safety and effectiveness of different medications such as Remdesivir (marketed as Veklury
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Prevalence of Potential Drug Interactions With Direct-Acting Antivirals for COVID-19 Among Hospitalized Patients. (Pubmed Central) - Oct 30, 2024
Higher age and comorbidity burden were significantly associated with a higher likelihood of receiving medications that are "Contraindicated" with nirmatrelvir/ritonavir. In the evolving COVID-19 era, these findings provide insights into patients hospitalized for COVID-19, and the polypharmacy evaluations that clinicians may encounter when selecting among DAAs to manage COVID-19.
- |||||||||| Rituxan (rituximab) / Roche
Journal: Organising pneumonia due to inadequately cleared COVID-19 infection while on rituximab. (Pubmed Central) - Oct 27, 2024
It was thought that he did not clear his prior COVID-19 infection due to his immunocompromised state while taking rituximab. On recommendation of infectious disease, he was treated with a prolonged course of nirmatrelvir/ritonavir, remdesivir and corticosteroids with significant symptom improvement.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal, Adverse events: Pharmacovigilance of Drug-Drug Interactions with Nirmatrelvir/Ritonavir. (Pubmed Central) - Oct 27, 2024
On recommendation of infectious disease, he was treated with a prolonged course of nirmatrelvir/ritonavir, remdesivir and corticosteroids with significant symptom improvement. Low reporting rates of DDIs support the potential for NMV/r treatment to be safely managed with careful use of available drug interaction resources to aid in risk mitigation.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xocova (ensitrelvir) / Shionogi, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Review, Journal: Emerging small-molecule antiviral agents in long COVID prevention. (Pubmed Central) - Oct 24, 2024
Recent evidence indicated that early antiviral intervention-particularly with small-molecule drugs such as Metformin, Ensitrelvir, Molnupiravir, and Nirmatrelvir-may effectively reduce the incidence of long COVID. This underscored the promising role of small-molecule compounds in mitigating long-term COVID-19 consequences, offering a novel preventive strategy against long COVID and its extensive impacts on patients.
- |||||||||| Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Review, Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review. (Pubmed Central) - Oct 23, 2024
This underscored the promising role of small-molecule compounds in mitigating long-term COVID-19 consequences, offering a novel preventive strategy against long COVID and its extensive impacts on patients. This systematic literature review suggests continued effectiveness of sotrovimab in preventing severe clinical outcomes during BA.2 and BA.5 predominance, both against active/untreated comparators and compared with BA.1 predominance.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Two Cases of Reactivated TB developed in Patients with Outpatient Treatment for COVID-19 Infection (SAPPHIRE; B1F) - Oct 21, 2024 - Abstract #KATRDIC2024KATRDIC_496;
Ten days ago, he was diagnosed COVID-19 and treated with Paxlovid in outpatient clinic...In fact, he was told a possibility of TB due to abnormal infiltrations at the left upper lobe in other hospital a few months ago and there were no positive results for M.TB at that time. Conclusion The currents cases reveal the evidence of a potential role of COVID-19 on TB reactivation.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Clinical effectiveness of oral antivirals for non-hospitalized adult COVID-19 patients aged 18-60 years. (Pubmed Central) - Oct 18, 2024
The antiviral group also exhibited a reduced risk of individual secondary outcomes, including emergency department visits (HR 0.780, 95% CI, 0.738-0.825), hospitalization (HR 0.755, 95% CI, 0.715-0.840), and mortality (HR 0.297, 95% CI, 0.147-0.600). Oral antiviral agents were associated with lower risks of all-cause emergency department visits, hospitalizations, and mortality in non-hospitalized COVID-19 patients aged <60?years.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Molecular Mechanism-Driven Discovery of Novel Small Molecule Inhibitors against Drug-Resistant SARS-CoV-2 Mpro Variants. (Pubmed Central) - Oct 10, 2024
Under the selective pressure of nirmatrelvir, a peptidomimetic covalent drug targeting SARS-CoV-2 Mpro, various drug-resistant mutations on Mpro have been acquired in vitro...The binding modes referring to NMI-003-Mpro_E166V and NMI-003-Mpro_L50F+E166V were further elucidated at the atomic level. In summary, NMI-003 reported herein is the first compound with activity against E166V and L50F+E166V, which provides a good starting point to design novel antiviral drugs for the treatment of drug-resistant SARS-CoV-2.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Review, Journal: Long COVID syndrome: An unfolding enigma. (Pubmed Central) - Oct 9, 2024
Several clinical trials are underway for the treatment of long COVID and the results of these are eagerly awaited. Physical and mental rehabilitation at home, at community level or in the hospital setting as appropriate is essential in patients with long COVID.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Insights into the Main Protease of SARS-CoV-2: Thermodynamic Analysis, Structural Characterization, and the Impact of Inhibitors. (Pubmed Central) - Oct 8, 2024
The main protease (Mpro) of SARS-CoV-2 is an essential enzyme for coronaviral maturation and is the target of Paxlovid, which is currently the standard-of-care treatment for COVID-19...The overall energy landscape was obtained using variable temperature nanoelectrospray ionization (vT-nESI), thus providing quantitative evaluation of inhibitor binding on the stability of Mpro. Thermodynamic parameters extracted from van't Hoff plots revealed that the dimeric complexes containing each inhibitor showed enhanced stability through increased melting temperatures as well as overall lower average charge states, giving insight into the basis for inhibition mechanisms.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: A Majority Of Americans Have No Or Low Awareness Of Paxlovid, The At-Home COVID-19 Treatment. (Pubmed Central) - Oct 7, 2024
Results suggest that Paxlovid underuse may be partly driven by a lack of effective public communication to generate awareness and knowledge about the drug, leading to low demand. As Paxlovid loses full government subsidies, further public outreach is needed to ensure that the public accesses it when needed.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
Clinical data, Retrospective data, Journal, Monotherapy: Does early combination vs. Monotherapy improve clinical outcomes of clinically extremely vulnerable patients with COVID-19? Results from a retrospective propensity-weighted analysis. (Pubmed Central) - Oct 5, 2024
Early combination therapy showed a favourable impact on a composite outcome (including mortality, hospitalizations and access to emergency department) in severely immunocompromised hosts who were all vaccinated. However, further studies are needed to support our results.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, bebtelovimab (LY-CoV1404) / AbCellera, Eli Lilly, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Journal: Reprint of: Evaluation of physicians prescribing of COVID-19 guideline-directed outpatient treatments in a primary care walk-in clinic. (Pubmed Central) - Oct 3, 2024
Nirmatrelvir-ritonavir was the most prescribed medication for the treatment of mild-to-moderate COVID-19, consistent with its position as first-line therapy and widespread accessibility. The study results will inform future educational opportunities, such as in-service presentations and handouts, that may improve the prescribing of outpatient treatment for mild-to-moderate COVID-19 moving forward.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Prolonged course of Paxlovid administration in a centenarian with COVID-19: A case report. (Pubmed Central) - Oct 2, 2024
The study results will inform future educational opportunities, such as in-service presentations and handouts, that may improve the prescribing of outpatient treatment for mild-to-moderate COVID-19 moving forward. This case suggests that Paxlovid can be used cautiously in centenarians with renal insufficiency and two courses of treatment can be considered in patients with persistent positive nucleic acid.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Myrtus communis L. Essential Oil Exhibits Antiviral Activity against Coronaviruses. (Pubmed Central) - Sep 29, 2024
Artificial bacterial chromosome plasmids that expressed SARS-CoV-2 used for replicon-to determine viral replication and viral assembly/egress on HEK293T/17 cells-and virus-like particles on Huh7.5-AT cells-to determine viral entry and assembly/egress-showed no antiviral activity with MEO in comparison to Remdesivir. This study reveals the potential effectiveness of MEO as an alternative natural remedy to treat human coronaviruses and a potential antiviral agent for future coronavirus infections.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
STRATIFYING RISK FOR LONG COVID IN PATIENTS WITH IMMUNODEFICIENCY (Monitor 26; Hall A) - Sep 29, 2024 - Abstract #ACAAI2024ACAAI_1023;
Our study further suggests that Paxlovid could be an effective strategy in reducing the risk of PASC among immunodeficiency patients. Future prospective studies are necessary to confirm these findings.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, HEOR: PROLIFIC: imPROving Quality of LIFe In the Long COVID Patient (clinicaltrials.gov) - Sep 26, 2024
P2, N=180, Active, not recruiting,
Future prospective studies are necessary to confirm these findings. Recruiting --> Active, not recruiting | N=400 --> 180 | Trial completion date: Mar 2024 --> Nov 2024 | Trial primary completion date: Jan 2024 --> Nov 2024
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Identifying Veterans Who Benefit From Nirmatrelvir-Ritonavir: A Target Trial Emulation. (Pubmed Central) - Sep 26, 2024
Nirmatrelvir-ritonavir was effective in reducing 30-day hospitalization and death in older veterans, those at highest predicted risk for severe outcomes, and immunocompromised groups. Benefit was not observed in younger veterans or groups at lower predicted risk for hospitalization and death.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: Emerging SARS-CoV-2 Resistance After Antiviral Treatment. (Pubmed Central) - Sep 25, 2024
In this cohort study of 156 participants, treatment-emergent nirmatrelvir resistance mutations were commonly detected, especially in individuals who were immunosuppressed. However, these mutations were generally present at low frequencies and were transient in nature, suggesting a low risk for the spread of nirmatrelvir resistance in the community with the current variants and drug usage patterns.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer, Lagevrio (molnupiravir) / Ridgeback Biotherap, Merck (MSD)
Review, Journal: The Impact of Antidepressants on COVID-19 and Post-Acute COVID-19 Syndrome: A Scoping-Review Update (Pubmed Central) - Sep 23, 2024
In regions where neither vaccines nor antiviral agents currently approved for the prevention or treatment of COVID-19 are available, AD and in particular fluvoxamine would be a cost-effective alternative to protect against a severe course, even if this AD appears to have a smaller effect against COVID-19 than the currently approved antiviral agents, but with presumably better tolerability. A direct comparative clinical trial with approved antiviral agents is still pending and should be positive to further open the door for a guideline-based recommendation of fluvoxamine (or perhaps even AD) for COVID-19 or its aftermath.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
Journal: A potential allosteric inhibitor of SARS-CoV-2 main protease (Mpro) identified through metastable state analysis. (Pubmed Central) - Sep 23, 2024
Anti-COVID19 drugs, such as nirmatrelvir, have been developed targeting the SARS-CoV-2 main protease, Mpro, based on the critical requirement of its proteolytic processing of the viral polyproteins into functional proteins essential for viral replication...Finally, we tested the three compounds in vitro using a BRET-based Mpro biosensor and found that one of the compounds (ZINC4497834) inhibited the Mpro activity. We envisage that the identification of a potential allosteric inhibitor of Mpro will aid in developing improved anti-COVID-19 therapy.
- |||||||||| Paxlovid (nirmatrelvir/ritonavir) / Pfizer
PK/PD data, Journal: Target Attainment and Population Pharmacokinetics of Nirmatrelvir/Ritonavir in Critically Ill Adult Patients. (Pubmed Central) - Sep 23, 2024
Based on our dosing simulations, the initial dosage of NIR/RIT was 300mg/100mg twice a day in critically ill patients with CrCL>45 mL/min; When CrCL in critically ill patients is between 15 and 45 mL/min, NIR/RIT is 150mg/100mg twice a day. The maintenance dose is adjusted according to CrCL and AUC of RIT, with the dosages varying between 75mg/100mg and 300mg/100mg.
|
